Merck 2014 Annual Report Download - page 78

Download and view the complete annual report

Please find page 78 of the 2014 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 271

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200
  • 201
  • 202
  • 203
  • 204
  • 205
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • 215
  • 216
  • 217
  • 218
  • 219
  • 220
  • 221
  • 222
  • 223
  • 224
  • 225
  • 226
  • 227
  • 228
  • 229
  • 230
  • 231
  • 232
  • 233
  • 234
  • 235
  • 236
  • 237
  • 238
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • 246
  • 247
  • 248
  • 249
  • 250
  • 251
  • 252
  • 253
  • 254
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • 265
  • 266
  • 267
  • 268
  • 269
  • 270
  • 271

73GROUP MANAGEMENT REPORT → FUNDAMENTAL INFORMATION ABOUT THE GROUP → Research and development at the group
BIOPHARMACEUTICALS PIPELINE,
AS OF DECEMBER 31, 2014
Therapeutic area Compound Indication Status
Oncology Evofosfamide (TH-302; hypoxia-activated prodrug) Soft tissue sarcoma Phase III
Evofosfamide (TH-302; hypoxia-activated prodrug) Pancreatic cancer Phase III
Evofosfamide (TH-302; hypoxia-activated prodrug) Non-small cell lung cancer Phase II
Evofosfamide (TH-302; hypoxia-activated prodrug) Melanoma Phase II
Evofosfamide (TH-302; hypoxia-activated prodrug) Hematological malignancies & solid tumors Phase I
Abituzumab (DI17E6; anti-integrin mAb) Colorectal cancer Phase II
Pimasertib (MEK inhibitor) Melanoma Phase II
Pimasertib / hDM2 inhibitor combination Solid tumors Phase I1
Tepotinib (MSC 2156119J; c-Met kinase inhibitor) Solid tumors Phase I
MSC 2363318A (P70S6K and Akt inhibitor) Solid tumors Phase I
BGB-283 (BRAF inhibitor) Solid tumors Phase I
BGB-290 (PARP inhibitor) Solid tumors Phase I
MSC 2490484A (DNA-PK inhibitor) Solid tumors Phase I
Immuno-Oncology MSB 0010360N (NHS-IL12; cancer immunotherapy) Solid tumors Phase I2
Avelumab (MSB 0010718C; anti-PD-L1 mAb) Merkel cell skin carcinoma Phase II
Avelumab (MSB 0010718C; anti-PD-L1 mAb) Solid tumors Phase I
Immunology Atacicept (anti-Blys / anti-APRIL fusion protein) Systemic lupus erythematosus Phase II
Sprifermin (fibroblast growth factor 18) Osteoarthritis Phase II
MSB 0010841 (ALX-0761; anti-IL-17 A / F nanobody) Psoriasis Phase I
MSC 2364447 (BTK inhibitor) Healthy volunteers Phase I
Neurodegenerative
Diseases ATX-MS-1467 (immune-tolerizing agent) Multiple sclerosis Phase II
Fertility
Pergoveris® (follitropin alfa and lutropin alpha)
Assisted Reproductive Technology,
poor ovarian responders Phase III
Endocrinology
Kuvan® (sapropterin dihydrochloride) PKU in pediatric patients < 4 years
Submitted for
approval3
1 Combined with hDM2 inhibitor (SAR405838) from Sanofi, conducted under the responsibility
of Sanofi.
2 Sponsored by the National Cancer Institute (USA).
3 Post-approval request by the European Medicines Agency (EMA). EMA application under review.
More information on ongoing clinical trials can be found at www.clinicaltrials.gov.
IL: Interleukin
hDM2: Human Double Minute 2 homolog
mAb: Monoclonal antibody
MEK: Mitogen Activated Protein Kinase
EGFR: Epidermal Growth Factor Receptor
PARP: Poly [ADP-Ribose] Polymerase
BTK: Bruton’s Tyrosine Kinase
PKU: Phenylketonuria